Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 155

1.

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

Martinez FJ, Boscia J, Feldman G, Scott-Wilson C, Kilbride S, Fabbri L, Crim C, Calverley PM.

Respir Med. 2013 Apr;107(4):550-9. doi: 10.1016/j.rmed.2012.12.016. Epub 2013 Jan 16. Erratum in: Respir Med. 2013 Dec;107(12):2092-3.

PMID:
23332861
[PubMed - indexed for MEDLINE]
Free Article
2.

A randomised trial of fluticasone furoate/vilanterol (50/25 μg; 100/25 μg) on lung function in COPD.

Kerwin EM, Scott-Wilson C, Sanford L, Rennard S, Agusti A, Barnes N, Crim C.

Respir Med. 2013 Apr;107(4):560-9. doi: 10.1016/j.rmed.2012.12.014. Epub 2013 Jan 23. Erratum in: Respir Med. 2013 Dec;107(12):2094.

PMID:
23352226
[PubMed - indexed for MEDLINE]
Free Article
3.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
[PubMed - indexed for MEDLINE]
4.

Efficacy and optimal dosing interval of the long-acting beta₂ agonist, vilanterol, in persistent asthma: a randomised trial.

Sterling R, Lim J, Frith L, Snowise NG, Jacques L, Haumann B.

Respir Med. 2012 Aug;106(8):1110-5. doi: 10.1016/j.rmed.2012.03.007. Epub 2012 Apr 19.

PMID:
22520084
[PubMed - indexed for MEDLINE]
Free Article
5.

The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.

Hanania NA, Feldman G, Zachgo W, Shim JJ, Crim C, Sanford L, Lettis S, Barnhart F, Haumann B.

Chest. 2012 Jul;142(1):119-27. doi: 10.1378/chest.11-2231.

PMID:
22241764
[PubMed - indexed for MEDLINE]
6.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.

Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.

PMID:
24429127
[PubMed - indexed for MEDLINE]
7.

28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial.

Feldman G, Walker RR, Brooks J, Mehta R, Crater G.

Pulm Pharmacol Ther. 2012 Dec;25(6):465-71. doi: 10.1016/j.pupt.2012.08.007. Epub 2012 Aug 31.

PMID:
22955035
[PubMed - indexed for MEDLINE]
8.

Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.

Bollmeier SG, Prosser TR.

Ann Pharmacother. 2014 Feb;48(2):250-7. doi: 10.1177/1060028013512615. Epub 2013 Nov 19. Review.

PMID:
24259654
[PubMed - indexed for MEDLINE]
9.

Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone.

Bateman ED, O'Byrne PM, Busse WW, Lötvall J, Bleecker ER, Andersen L, Jacques L, Frith L, Lim J, Woodcock A.

Thorax. 2014 Apr;69(4):312-9. doi: 10.1136/thoraxjnl-2013-203600. Epub 2013 Nov 19.

PMID:
24253831
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination.

Oliver A, Bjermer L, Quinn D, Saggu P, Thomas P, Yarnall K, Lötvall J.

Allergy. 2013 Sep;68(9):1136-42. doi: 10.1111/all.12205. Epub 2013 Aug 7.

PMID:
23924233
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD.

Agustí A, de Teresa L, De Backer W, Zvarich MT, Locantore N, Barnes N, Bourbeau J, Crim C.

Eur Respir J. 2014 Mar;43(3):763-72. doi: 10.1183/09031936.00054213. Epub 2013 Oct 10.

PMID:
24114969
[PubMed - indexed for MEDLINE]
12.

Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the β2 agonist vilanterol administered once daily for 52 weeks in patients >=12 years old with asthma: a randomised trial.

Busse WW, O'Byrne PM, Bleecker ER, Lötvall J, Woodcock A, Andersen L, Hicks W, Crawford J, Jacques L, Apoux L, Bateman ED.

Thorax. 2013 Jun;68(6):513-20. doi: 10.1136/thoraxjnl-2012-202606. Epub 2013 Feb 25.

PMID:
23440247
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma.

O'Byrne PM, Bleecker ER, Bateman ED, Busse WW, Woodcock A, Forth R, Toler WT, Jacques L, Lötvall J.

Eur Respir J. 2014 Mar;43(3):773-82. doi: 10.1183/09031936.00064513. Epub 2013 Oct 17.

PMID:
24136330
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Inhaled fluticasone furoate/vilanterol does not affect hypothalamic-pituitary-adrenal axis function in adolescent and adult asthma: randomised, double-blind, placebo-controlled study.

Allen A, Schenkenberger I, Trivedi R, Cole J, Hicks W, Gul N, Jacques L.

Clin Respir J. 2013 Oct;7(4):397-406. doi: 10.1111/crj.12026. Epub 2013 Jun 5.

PMID:
23578031
[PubMed - indexed for MEDLINE]
Free Article
15.

Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.

Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.

Respir Med. 2013 Oct;107(10):1538-46. doi: 10.1016/j.rmed.2013.06.001. Epub 2013 Jul 2.

PMID:
23830094
[PubMed - indexed for MEDLINE]
Free Article
16.

Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial.

Lötvall J, Bakke PS, Bjermer L, Steinshamn S, Scott-Wilson C, Crim C, Sanford L, Haumann B.

BMJ Open. 2012 Jan 19;2(1):e000370. doi: 10.1136/bmjopen-2011-000370. Print 2012.

PMID:
22267687
[PubMed]
Free PMC Article
17.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects.

Kempsford R, Allen A, Kelly K, Saggu P, Crim C.

Br J Clin Pharmacol. 2014 Mar;77(3):466-79. doi: 10.1111/bcp.12243.

PMID:
24093504
[PubMed - indexed for MEDLINE]
Free Article
18.
19.

Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.

Kempsford R, Norris V, Siederer S.

Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.

PMID:
23232038
[PubMed - indexed for MEDLINE]
20.

Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial.

Busse WW, Bleecker ER, Bateman ED, Lötvall J, Forth R, Davis AM, Jacques L, Haumann B, Woodcock A.

Thorax. 2012 Jan;67(1):35-41. doi: 10.1136/thoraxjnl-2011-200308. Epub 2011 Aug 9.

PMID:
21828231
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk